Arix Bioscience (LSE:ARIX) Debt-to-Equity : 0.00 (As of Jun. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Arix Bioscience Debt-to-Equity?

Arix Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.04 Mil. Arix Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2023 was £0.00 Mil. Arix Bioscience's Total Stockholders Equity for the quarter that ended in Jun. 2023 was £239.12 Mil. Arix Bioscience's debt to equity for the quarter that ended in Jun. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Arix Bioscience's Debt-to-Equity or its related term are showing as below:

During the past 7 years, the highest Debt-to-Equity Ratio of Arix Bioscience was 0.01. The lowest was 0.00. And the median was 0.00.

LSE:ARIX's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.14
* Ranked among companies with meaningful Debt-to-Equity only.

Arix Bioscience Debt-to-Equity Historical Data

The historical data trend for Arix Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arix Bioscience Debt-to-Equity Chart

Arix Bioscience Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Debt-to-Equity

Get a 7-Day Free Trial

0.01

Arix Bioscience Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Debt-to-Equity	Get a 7-Day Free Trial								-	-	-	-	-

Competitive Comparison of Arix Bioscience's Debt-to-Equity

For the Biotechnology subindustry, Arix Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arix Bioscience's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arix Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Arix Bioscience's Debt-to-Equity falls into.

Arix Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Arix Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.059	+	0.011)	/	225.913
	=	0.00

Arix Bioscience's Debt to Equity Ratio for the quarter that ended in Jun. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.037	+	0)	/	239.12
	=	0.00

Arix Bioscience (LSE:ARIX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Arix Bioscience Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Arix Bioscience's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Arix Bioscience (LSE:ARIX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arix Bioscience PLC (LSE:ARIX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 Duke Street, Duke Street House, London, GBR, W1K 6JL

Website

https://www.arixbioscience.com

Arix Bioscience PLC is a healthcare and life science company. Its business model is to source, finance, and develop healthcare and life science businesses that deliver or seek to deliver therapies to patients. Its segment includes sourcing, financing, and developing healthcare and life science businesses globally.

Arix Bioscience (LSE:ARIX) Headlines

No Headlines